MCID: CMM003
MIFTS: 28

Common Wart

Categories: Infectious diseases, Skin diseases

Aliases & Classifications for Common Wart

MalaCards integrated aliases for Common Wart:

Name: Common Wart 12 15 17 71

Classifications:



External Ids:

Disease Ontology 12 DOID:11165
ICD9CM 34 078.1
NCIt 50 C27087
SNOMED-CT 67 57019003
ICD10 32 B07.8
UMLS 71 C0043037

Summaries for Common Wart

Disease Ontology : 12 A viral infectious disease that results in infection located in skin, has material basis in human papillomavirus (types 2 and 4). This infection has symptom raised wart with roughened surface, most common on hands, but can grow anywhere on the body.

MalaCards based summary : Common Wart is related to angiokeratoma of fordyce and focal epithelial hyperplasia, and has symptoms including raised wart An important gene associated with Common Wart is C12orf71 (Chromosome 12 Open Reading Frame 71). The drugs Vaccines and Hydrogen peroxide have been mentioned in the context of this disorder. Affiliated tissues include skin.

Related Diseases for Common Wart

Graphical network of the top 20 diseases related to Common Wart:



Diseases related to Common Wart

Symptoms & Phenotypes for Common Wart

Symptoms:

12
  • raised wart

Drugs & Therapeutics for Common Wart

Drugs for Common Wart (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 23)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1 Vaccines Phase 4
2
Hydrogen peroxide Approved, Vet_approved Phase 3 7722-84-1 784
3
Furosemide Approved, Vet_approved Phase 3 54-31-9 3440
4 Pharmaceutical Solutions Phase 3
5 Anti-Infective Agents Phase 3
6 Anti-Infective Agents, Local Phase 3
7 diuretics Phase 3
8 Sodium Potassium Chloride Symporter Inhibitors Phase 3
9
Cantharidin Approved, Investigational Phase 2 56-25-7
10
Ethanol Approved Phase 2 64-17-5 702
11
Vitamin D3 Approved, Nutraceutical Phase 2 67-97-0 6221 5280795
12
Vitamin A Approved, Nutraceutical, Vet_approved Phase 2 68-26-8, 11103-57-4 445354
13
Vitamin D Approved, Nutraceutical, Vet_approved Phase 2 1406-16-2
14 Trace Elements Phase 2
15 Micronutrients Phase 2
16 retinol Phase 2
17 Vitamins Phase 2
18 Retinol palmitate Phase 2
19 Hormones Phase 2
20 Calcium, Dietary Phase 2
21 Calciferol Phase 2
22 Nutrients Phase 2
23
Calcium Nutraceutical Phase 2 7440-70-2 271

Interventional clinical trials:

(show all 33)
# Name Status NCT ID Phase Drugs
1 Intralesional Measles, Mumps, Rubella (MMR) Vaccine Versus Cryotherapy in Treatment of Multiple Common and Planter Warts : a Randomized Controlled Trial Completed NCT03183765 Phase 4 Measles-Mumps-Rubella Vaccine
2 Study to Evaluate the Efficacy of 2LVERU® JUNIOR and 2LVERU® on the Treatment of Warts. Recruiting NCT03977753 Phase 4 2LVERU® or 2LVERU® JUNIOR;Placebo
3 A Phase 3 Open Label Safety Study of A-101 Topical Solution for the Treatment of Common Warts Completed NCT03812510 Phase 3 A-101
4 A Phase 3 Randomized, Double-Blind, Vehicle-Controlled, Parallel-Group Study of A-101 Topical Solution Applied Twice a Week in Subjects With Common Warts Completed NCT03691831 Phase 3 Active
5 A Phase 3 Randomized, Double-Blind, Vehicle-Controlled, Parallel Group Study of A-101 Topical Solution Applied Twice a Week in Subjects With Common Warts Completed NCT03687372 Phase 3 A-101
6 A Phase 3, Randomized, Double-Blind, Vehicle-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of CLS006 Versus Vehicle in Subjects 2 Years of Age or Older With Cutaneous Common Warts Completed NCT02971891 Phase 3 CLS006 (Furosemide) Topical Gel;Vehicle Topical Gel
7 A Phase 3, Randomized, Double-Blind, Vehicle-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of CLS006 Versus Vehicle in Subjects 2 Years of Age or Older With Cutaneous Common Warts Completed NCT03259620 Phase 3 CLS006;CLS006 Vehicle
8 Efficacy of Cryotherapy Combined With Intralesional Tuberculin Purified Protein Derivative (PPD) Versus Interlesional Tuberculin PPD Monotherapy in the Treatment of Multiple Common Warts Not yet recruiting NCT04288817 Phase 3
9 A Prospective, Phase 2a Study to Evaluate the Effectiveness and Safety of DPCP Ointment (Samcyprone™) on the Clearance of Verruca Vulgaris (Common Warts) in Subjects Ages 18 - 65 Years Unknown status NCT02640820 Phase 2 Sensitizing DPCP Ointment;Treatment DPCP Ointment
10 ALC-919 For The Treatment Of Common Warts (Verruca Vulgaris) Completed NCT02483455 Phase 2 2014-ALC-919-US;Vehicle-Control Topical Solution
11 A Phase 2, Open Label Study to Evaluate the Efficacy, Safety and Tolerability of VP-102 in Subjects With Common Warts (Verruca Vulgaris) Completed NCT03487549 Phase 2 VP-102-cantharidin topical film forming solution
12 A Randomized, Double-Blind, Vehicle-Controlled, Parallel Group Study of A-101 Topical Solution Applied Once a Week in Subjects With Common Warts Completed NCT03210337 Phase 2 A-101 Topical Solution;A-101 Vehicle Solution
13 A Randomized, Double-Blind, Vehicle-Controlled, Parallel Group Study of A-101 Topical Solution Applied Twice a Week in Subjects With Common Warts Completed NCT03278028 Phase 2 A-101 Topical Solution;A-101 Vehicle Solution
14 A Randomized, Double-blind, Multi-center, Placebo-controlled, Dose-ranging, Efficacy and Safety Trial of a New Botanical Drug Product Containing East Indian Sandalwood Oil (EISO) for Treatment of Common Warts (Verruca Vulgaris) Completed NCT01286441 Phase 2 10% EISO;Placebo;20% EISO;30% EISO
15 Active-Controlled Study to Assess the Efficacy and Safety of DFD-05 in Subjects With Common Warts Completed NCT02798419 Phase 2 DFD05 Cream;Active01 Cream
16 A Randomized, Double-Blind, Vehicle-Controlled, Parallel Group Study of A-101 Solution in Subjects With Common Warts. Completed NCT02669862 Phase 2 A-101 Solution 40;A-101 Solution 45;Vehicle Solution
17 A Single-Blind, Dose-Escalating Study to Assess Efficacy and Safety of Resiquimod Gel Applied 3 Times Per Week for up to 12 Weeks for the Treatment of Common Warts in Pediatric Subjects Completed NCT00116662 Phase 2 Resiquimod
18 A Three-Stage, Modified-Blind, Dose-Escalating Study to Assess Efficacy and Safety of Resiquimod Gel Applied 3 Times Per Week for 4 Weeks for the Treatment of Common Warts in Adults Completed NCT00115141 Phase 2 Resiquimod
19 Study of the Safety and Effectiveness of Candin for the Treatment of Common Warts Completed NCT01757392 Phase 2
20 A Single-Blind, Dose-Escalating Study to Assess Efficacy and Safety of Resiquimod Gel Applied 3 Times Per Week for 4 Weeks for the Treatment of Common Warts in Pediatric Subjects Completed NCT00116675 Phase 2 Resiquimod
21 A Three-Stage, Modified-Blind, Dose-Escalating Study to Assess Efficacy and Safety of Resiquimod Gel Applied 5 Times Per Week for 4 Weeks for the Treatment of Common Warts in Adults Completed NCT00117923 Phase 2 Resiquimod
22 A Three-Stage, Modified-Blind, Dose-Escalating Study to Assess Efficacy and Safety of Resiquimod Gel for the Treatment of Common Warts in Adults Completed NCT00114920 Phase 2 Resiquimod
23 A Two-Stage, Single-Blind, Dose-Escalating Study to Assess Efficacy and Safety of Resiquimod Gel Applied 5 Times Per Week for up to 12 Weeks for the Treatment of Common Warts in Adults Completed NCT00117871 Phase 2 Resiquimod
24 A Phase IIa, Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Varying Regimens of CANDIN for Treatment of Common Warts (Verruca Vulgaris) Completed NCT02393417 Phase 2
25 Efficacy of Intralesional Vitamin D Injection for Treatment of Common Warts: A Randomized Controlled Trial Recruiting NCT04278573 Phase 2 Vitamin D3;Placebo
26 A Double-blind, Randomized, Vehicle-controlled, Parallel-group, Phase II Dose-ranging Study to Evaluate the Efficacy and Safety of SR-T100 Gel in Common Warts (CW) Patients. Suspended NCT01796795 Phase 2 Vehicle gel;SR-T100 gel with 1.0% of SM;SR-T100 gel with 2.3% of SM
27 An Open Label Exploratory Study Evaluating the Efficacy and Safety of Ingenol Mebutate 0.05% Gel for the Treatment of Verruca Vulgaris. Completed NCT02748902 Phase 1 ingenol mebutate 0.05% gel
28 A Randomized, Placebo-controlled, Double-blind Phase I Study to Explore Safety, Tolerability and Pharmacodynamics of CyPep-1 in Subjects With Cutaneous Warts Recruiting NCT03846648 Phase 1 Cypep-1
29 A Phase I, Single-Centre, Open-Label, Fixed-Dose Study of the Safety and Efficacy of up- to Three-Days Application of 0.05% PEP005 Topical Gel in the Treatment of Patients With Common Wart(s) (Verruca[e] Vulgaris) on the Dorsal Hand Withdrawn NCT00546611 Phase 1 PEP005
30 Comparative Evaluation of Carbon Dioxide Laser and Cryotherapy by Dermoscopy in Treatment of Viral Wart Unknown status NCT03166137
31 Double-Blind, Randomized Control Trial To Evaluate the Efficacy of Duct Tape Versus Placebo for the Treatment of Verruca Vulgaris Completed NCT00328991
32 Nanopulse Efficacy Study for the Treatment of Common Warts Completed NCT02650466
33 A Multicenter, Prospective, Randomized, Comparison IDE Study Between the Pulse Biosciences CellFX System and Cryosurgery for the Treatment of Cutaneous Non-Genital Common Warts Recruiting NCT04738734

Search NIH Clinical Center for Common Wart

Genetic Tests for Common Wart

Anatomical Context for Common Wart

The Foundational Model of Anatomy Ontology organs/tissues related to Common Wart:

19
Skin

MalaCards organs/tissues related to Common Wart:

40
Skin

Publications for Common Wart

Articles related to Common Wart:

(show top 50) (show all 77)
# Title Authors PMID Year
1
Digital squamous cell carcinoma associated with possibly carcinogenic human papillomavirus type 73 (HPV73): a case report. 61
33348942 2020
2
Cryosurgical ablation for treatment of common warts on the nasal vestibule. 61
32682612 2020
3
Determination of Causative Human Papillomavirus Type in Tissue Specimens of Common Warts Based on Estimated Viral Loads. 61
32039037 2020
4
Local hyperthermia cleared multifarious viral warts in a patient with Cushing's syndrome. 61
30633835 2019
5
Cryotherapy vs trichloroacetic acid 90% in treatment of common warts. 61
30358072 2019
6
Acquired digital fibrokeratoma: review of its clinical and dermoscopic features and differential diagnosis. 61
29777543 2019
7
Prevalence and factors associated with warts in primary school children in Tema District, Sohag Governorate, Egypt. 61
30774146 2019
8
Filiform Verrucous Sarcoidosis of the Face: A Warty Report. 61
29502440 2018
9
Use of trichloroacetic acid for management of oral lesions caused by human papillomavirus. 61
29513235 2018
10
Verruca vulgaris of the buccal mucosa: A case report. 61
29516939 2018
11
[A case of combination therapy by vacuum assisted closure along with skin graft for scleroderma with common wart]. 61
27640802 2016
12
HLA Immunogenotype Determines Persistent Human Papillomavirus Virus Infection in HIV-Infected Patients Receiving Antiretroviral Treatment. 61
26908737 2016
13
Onychoheterotopia Due to a Traumatically Transplanted Nail in a Child. 61
26584701 2015
14
Monochloroacetic acid application is an effective alternative to cryotherapy for common and plantar warts in primary care: a randomized controlled trial. 61
25584800 2015
15
Hyperkeratotic acral melanoma mimicking a common wart. 61
25973355 2015
16
Candida skin test reagent as a novel adjuvant for a human papillomavirus peptide-based therapeutic vaccine. 61
24135577 2013
17
Treatment of recalcitrant warts with Bacillus Calmette-Guérin: a promising new approach. 61
24552412 2013
18
[Viruses as agents inducing cutaneous neoplasms]. 61
23612818 2013
19
Keratotic horn on left fifth fingertip: congenital ectopic nail misdiagnosed as a common wart. 61
22277059 2013
20
Comparative study of topical 80% trichloroacetic acid with 35% trichloroacetic acid in the treatment of the common wart. 61
23135096 2012
21
Successful clearance of facial common warts by local hyperthermia: report of two cases. 61
22950567 2012
22
[The acrolentiginous melanoma: how to recognise and when to refer?]. 61
22914059 2012
23
HPV-associated oral warts. 61
21608502 2011
24
[The enhancement of DNA binding ability of a mutated E2 (A338V) protein of HPV-2]. 61
20572344 2010
25
Disfiguring generalized verrucosis in an indonesian man with idiopathic CD4 lymphopenia. 61
20083696 2010
26
Efficacy of 80% phenol solution in comparison with cryotherapy in the treatment of common warts of hands. 61
19122958 2008
27
[Transcriptional repressive activity of mutated E2 protein of human papillomavirus 2 (HPV-2) variant]. 61
18780628 2008
28
Treatment options for the common wart. 61
18210913 2007
29
Plantar verrucous carcinoma (epithelloma cuniculatum): rare form of the common wart. 61
17214114 2006
30
Human papillomavirus associated with Bowen's disease of the finger. 61
15729868 2004
31
[The common wart]. 61
15026757 2004
32
Oral verruca vulgaris: report of a rare case. 61
15682794 2004
33
Seasonal variation of dermatologic disease in the USA: a study of office visits from 1990 to 1998. 61
14693014 2004
34
[Human papillomaviruses]. 61
14610898 2003
35
Duct tape removes warts. 61
12585986 2003
36
Is duct tape occlusion therapy as effective as cryotherapy for the treatment of the common wart? 61
12361441 2002
37
The efficacy of duct tape vs cryotherapy in the treatment of verruca vulgaris (the common wart). 61
12361440 2002
38
CD4+ T lymphocytopenia with disseminated HPV. 61
12207745 2002
39
Protean manifestations of human papillomavirus type 60 infection on the extremities. 61
12000390 2002
40
Human papillomavirus associated Bowen's disease of the foot: unique clinical features mimicking a common wart. 61
11525958 2001
41
[A case of intestinal Behçet's disease with abnormal ossification complicated by myelodysplastic syndrome, symptoms revealed after the perforation of ileum ulcer]. 61
11021176 2000
42
[The CO2 laser and verruca vulgaris]. 61
11214484 2000
43
Many different papillomaviruses have low transcriptional activity in spite of strong epithelial specific enhancers. 61
10423140 1999
44
Condyloma acuminata: a fatal disease? 61
9798775 1998
45
Simultaneously detected aberrant p53 tumor suppressor protein and HPV-DNA localize mostly in separate keratinocytes in anogenital and common warts. 61
8734914 1996
46
Squamous cell carcinoma in situ (Bowen's disease) mimicking subungual verruca vulgaris. 61
7931119 1994
47
Efficacy of silver nitrate pencils in the treatment of common warts. 61
8051319 1994
48
Warts and lupus erythematosus. 61
8387376 1993
49
Efficacious treatment of the common wart (verruca vulgaris). 61
1462533 1992
50
[Laser flow cytofluorimetry in the study of papilloma virus-induced lesions]. 61
1963171 1990

Variations for Common Wart

Expression for Common Wart

Search GEO for disease gene expression data for Common Wart.

Pathways for Common Wart

GO Terms for Common Wart

Molecular functions related to Common Wart according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 pattern recognition receptor activity GO:0038187 8.96 TLR7 CLEC4E
2 mechanosensitive ion channel activity GO:0008381 8.62 TMC8 TMC6

Sources for Common Wart

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Mar-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....